ReneuRxâ„¢ (Nerve Selective Therapy) Utilized in Lateral Hip Pain (NCT07568015) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
ReneuRxâ„¢ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
100 participantsStarted 2026-05-01
Plain-language summary
The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRxâ„¢ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.
Who can participate
Age range22 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 22 to 80, inclusive of any gender
✓. Baseline pain intensity of \>5 of the Numeric Rating Scale (NRS) localized to the lateral aspect of the hip (with or without radiation to lateral thigh or buttock) despite current treatment
✓. Tenderness to palpation of the peritrochanteric space of the lateral hip in adults with Greater Trochanteric Pain Syndrome.
✓. At least 6 months of previous conservative treatments for subject's lateral hip pain (NSAID, acetaminophen, physical therapy, and/or cortisone injections) that are not currently providing relief
✓. Agree to see study investigator and study team for hip pain during the study period
✓. Willing/able to understand the informed consent form and provide written informed consent
✓. Able to complete outcome measures (including electronic patient reported outcome measures)
Exclusion criteria
✕. Known allergy to glycerol, hyaluronic acid, poloxamer 407, or phosphate buffered saline
✕. History of cryoglobulinemia
✕. History of cold-induced auto-immune hemolytic anemia (e.g. paroxysmal cold hemoglobinuria or cold agglutinin disease)
✕. History of cold urticaria
✕. History of Chilblain's (pernio) disease in the lower extremities
What they're measuring
1
Primary Effectiveness
Timeframe: 3-months post treatment
2
Primary Safety
Timeframe: Through study completion, an average of 12-months